Current Pediatrics Reports

, Volume 3, Issue 2, pp 137–145

The Clinical Trials Gap for Adolescents and Young Adults with Cancer: Recent Progress and Conceptual Framework for Continued Research

Hematology/Oncology (C Cole, Section Editor)

DOI: 10.1007/s40124-015-0075-y

Cite this article as:
Freyer, D.R. & Seibel, N.L. Curr Pediatr Rep (2015) 3: 137. doi:10.1007/s40124-015-0075-y
Part of the following topical collections:
  1. Hematology/Oncology


Over the past 30 years, adolescents and young adults (AYA, 15–39 years of age) with cancer have shown significantly less improvement in survival than younger and older patients. Because evidence suggests this may be related to their low participation in cancer clinical trials, increasing accrual to these trials has become a priority for closing this “AYA gap.” This paper reviews data documenting low AYA enrollment, presents a conceptual framework for research and intervention (Clinical Trials Pathway to Enrollment) and summarizes recent developments in the United States National Cancer Institute-sponsored clinical trials enterprise that are expected to improve AYA enrollment, including the National Clinical Trials Network (NCTN) and expanded scientific collaboration between the Children’s Oncology Group and adult NCTN groups. While time will be required for the effects of these changes to be fully realized, they offer a mechanism for facilitating the breadth of clinical/translational research needed for advancing AYA oncology and measuring its impact.


Adolescent and young adult (AYA) AYA gap Clinical trials Clinical trials accrual Clinical trials enrollment National Clinical Trials Network (NCTN) 

Copyright information

© Springer Science + Business Media New York 2015

Authors and Affiliations

  1. 1.Children’s Center for Cancer and Blood DiseasesChildren’s Hospital Los AngelesLos AngelesUSA
  2. 2.Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Pediatrics, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  3. 3.Cancer Therapy Evaluation ProgramNational Cancer InstituteBethesdaUSA

Personalised recommendations